Newer agents and combinations are needed in order to improve current results in 
ovarian cancer treatment. Gemcitabine is a novel agent that has shown consistent 
activity as a single agent in the treatment of platinum-resistant ovarian cancer 
and a favorable toxicity profile. Because of its clinical and preclinical 
synergism with platinum analogs, gemcitabine has been combined with carboplatin 
as a convincing approach in the treatment of platinum-sensitive recurrent 
ovarian cancer patients. Further combination of gemcitabine and other agents, 
including paclitaxel, is also feasible and has been actively studied in order to 
establish the role of gemcitabine in the management of treated and untreated 
ovarian cancer patients.